On Monday, 10 November 2025, the healthcare world was abuzz as two pharmaceutical giants, Pfizer and Novo Nordisk, fiercely ...

Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...

Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated ...

Metsera, the US biotech with a pipeline of next-generation metabolic hormone weight loss drugs, has agreed a sale to Pfizer ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Pharmaceutical giant Pfizer has finally acquired development-stage obesity drugmaker Metsera Inc., in an intense bidding war against the Danish drugmaker Novo Nordisk for over $10 billion.

Pfizer not only beat expectations last quarter, but also boosted its guidance.

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the ...

Companies don’t generally cut prices out of generosity.

Commissioner Marty Makary said the agency is asking drugmakers to remove the strict black box warnings, with the goal of encouraging more women to take them. Labels on the medicines currently list ...